YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial

YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial

Background: YF-H-2015005, a novel CXCR4 antagonist, has been proven to increase the quantities of circulating hematopoietic stem cells (HSCs), which results in an adequate collection of HSCs in non-Hodgkin lymphoma (NHL) patients.Methods: This was a multicenter, double-blind, randomized (1:1), place...

Full description

Bibliographic Details
Main Authors: Weiping Liu, Yufu Li, Quanshun Wang, Hang Su, Kaiyang Ding, Yuerong Shuang, Sujun Gao, Dehui Zou, Hongmei Jing, Ye Chai, Yicheng Zhang, Lihong Liu, Chunling Wang, Hui Liu, Jinying Lin, Haiyan Zhu, Chen Yao, Xiaoyan Yan, Meixia Shang, Shufang Wang, Fengyuan Chang, Xiaopei Wang, Jun Zhu, Yuqin Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Medicine
Subjects:
hematopoietic stem cell mobilization
therapeutics
treatment outcome
safety
lymphoma
non-Hodgkin
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.609116/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.609116/full

Similar Items